Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026

世界のトップ25バイオシミラー(バイオ後続品)メーカー分析2016-2026

◆タイトル:Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026
◆商品コード:VGAIN6041543
◆調査・発行会社:visiongain
◆発行日:2016年4月
◆ページ数:231
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥301,849見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥452,849見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥754,849見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のトップ25バイオシミラー(バイオ後続品)メーカー分析2016-2026"について調査・分析し、レポートサマリー、市場の促進要因、抑制要因、世界市場規模・市場予測、主要国別市場分析、市場環境分析、研究開発パイプライン分析、専門家の見解、結論などの情報をお届けいたします。

Biosimilar Drug Producers – Your 2016 Guide to Companies’ Activities and ProspectsWho are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover, in our updated survey, organisations’ outlooks from 2016. There you see results, trends, opportunities and revenue forecasting.

Visiongain’s new study analyses 25 leading developers, producers and marketers of biosimilars. That work also covers other firms, including big pharma companies entering that industry. There you assess potentials of established competitors and emerging players.

Our analysis is for everyone interested in the future of biopharma. Biosimilar drug sales expand fast, and that market holds great potential, especially after opening of the US market. See now how you could benefit your plans, decisions and authority.

Forecasts and other data to help you stay ahead in knowledge on those biological drugs
In our updated report you find analytical profiles of 25 leading biosimilar drug companies. There you analyse products, sales results, R&D and prospects. See qualitative analyses, too, for those biologics, also with discussions of many other relevant firms.

Our study gives you 115 tables, 11 charts and three interviews with companies. That survey lets you assess the most lucrative parts of the industry for biosimilar drugs (follow-on biologics or subsequent entry biologics). Explore the future of those therapeutic proteins for human medicine and assess their producers.

So explore changes affecting the biological drugs industry from 2016. The following sections outline what you get in our new investigation, showing how it can help your work.

Molecules giving rise to biosimilars – explore where progress occurs
First our report discusses biosimilar competition for these five therapeutic agents – products and research and development:
• Adalimumab
• Infliximab
• Etanercept
• Darbepoetin alpha
• Rituximab.

Large opportunities remain for biosimilars, with our study predicting high, rapid market expansion from 2016 to 2026. See what is possible. And discover where the best prospects exist and which companies are most likely to prosper.

That way you gain data and other knowledge to benefit your reputation for commercial insight. Assess products, technologies, activities and top biosimilar companies’ potentials.

Leading biosimilar drug companies – see what they are doing, including their prospects
In particular our survey analyses 25 leading biosimilar specialists worldwide. First of all, Chapter 4 gives profiles of leading biosimilar companies based in the US, Western Europe and Israel:
• Sandoz
• Teva Pharmaceutical Industries
• Hospira
• STADA Arzneimittel
• Mylan.

Chapter 5 profiles leading companies in China:
• 3SBio
• Qilu Pharmaceutical
• Shanghai Fosun Pharmaceutical Group
• Tonghua Dongbao Pharmaceutical Co.
• Beijing ShuangLu Pharmaceutical Co.

Chapter 6 profiles leading companies in India:
• Biocon
• Dr. Reddy’s Laboratories
• Wockhardt
• Zydus Cadila
• Ranbaxy
• Reliance Life Sciences
• Intas Biopharmaceuticals.

Chapter 7 profiles leading companies in Latin America:
• Probiomed
• Biosidus
• Amega Biotech.

Chapter 8 profiles leading companies in the rest of the world:
• Celltrion
• LG Life Sciences
• Dong-A
• Bioton
• Biocad.

Our report also reviews 25 other companies rising in importance. See what is possible from 2016, discovering what leading companies do and their commercial outlooks.

With our survey you explore who and what shapes the biosimilars industry, including policies and other forces influencing those companies and their market, affecting its revenues and profits. Discover what the future holds for leading organisations.

Issues affecting developers, producers and sellers of those biopharmaceuticals
Our investigation explains influences and events affecting the biosimilars industry and market from 2016, including these forces:
• Companies’ technologies, strategies, collaborations, products, R&D and results
• Emerging national markets and expanding therapeutic needs worldwide
• Big pharma entering that market – a trend shaping that industry.

And you assess these effects, among others:
• Patent expiries and resulting opportunities for follow-on products
• Innovative biologics, including biobetters, and their influence on biosimilar sales
• R&D for that market – assess technologies, clinical trials and opportunities, seeing how leading biosimilars companies adapt and progress.

There you examine political, economic, social and technological questions, assessing commercial outlooks. And you assess strengths, weaknesses, opportunities and threats affecting biosimilar drug companies’ activities and results.

Developing and developed national markets will prove important for biosimilar drug sales from 2016 to 2026. Discover what the future holds and the expected gains, including overall world revenue forecasting to 2026 for the biosimilars industry.

5 Ways Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026 helps you
Our new study helps your research, plans and analyses in these five main ways:
• Profiles of 25 leading biosimilar companies and other relevant firms – assess products, results, strategies, technologies and outlooks, also gaining company level revenue forecasting for five leading producers’ biosimilar drug sales
• R&D for biosimilars – see activities by company, finding what goes on in that industry, investigating its technological and commercial potentials
• Competition and opportunities – explore what affects the biosimilars market, finding what shapes its future, especially prospects for developing business
• Interviews with 3 companies – discover views to help you stay ahead in knowledge on that expanding drugs market
• Revenue forecasting to 2026 for that industry at world level – investigate overall sales potential there, seeing what revenue gains are possible.

【レポートの目次】

1. Report Overview
1.1 Overview of the Top Biosimilar Drug Manufacturers
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Biosimilar Drugs: World Market Forecast, 2016-2026
2.1 Introduction to Biologics and Biosimilars
2.1.1 Biologic Drugs Definition and Overview
2.1.2 Biosimilars Drugs Definition and Overview
2.1.3 How do Biosimilars Differ from Generics?
2.2 The World Biosimilar Market, 2015-2026
2.3 Overall World Biosimilars Revenue Forecast, 2016-2026
2.4 Biosimilars – Realising their Potential, Market Drivers
2.4.1 Biosimilar Approval Pathways and Regulations
2.4.2 Emerging Markets for Biosimilars
2.4.3 Start-up Pressure on Market Leaders
2.4.4 The Patent Cliff for Biologics
2.5 Biosimilars: Market Restraints
2.5.1 Market Fragmentation for Biosimilar Products
2.5.2 Innovative Biologics – Rendering Biosimilars Useless?
2.5.3 Biobetters – A Growing Threat

3. Leading Biosimilar Products: Overview, 2016
3.1 Humira: Product Overview
3.1.1 Adalimumab Biosimilars – Zydus Cadila
3.1.2 Adalimumab Biosimilars – Amgen-Actavis
3.1.3 Adalimumab Biosimilars – Sandoz
3.1.4 Adalimumab Biosimilars – Momenta Pharmaceuticals
3.1.5 Adalimumab Biosimilars – Pfizer
3.1.6 Adalimumab Biosimilars – Boehringer Ingelheim
3.2 Remicade: Product Overview
3.2.1 Infliximab Biosimilar – Epirus Pharmaceuticals & Ranbaxy
3.2.2 Infliximab Biosimilar – Celltrion & Hospira & Alvogen
3.3 Enbrel: Product Overview
3.3.1 Etanercept Biosimilar – Cipla & Shanghai CP Guojian
3.3.2 Etanercept Biosimilar – Daiichi Sankyo & Coherus Biosciences
3.4 Aranesp: Product Overview
3.4.1 Darbepoetin Alpha Biosimilar – Dr. Reddy’s Laboratories
3.4.2 Darbepoetin Alpha Biosimilar – Cipla & Hetero Drugs Limited
3.4.3 Darbepoetin Alpha Biosimilar – Hospira
3.5 Rituxan: Product Overview
3.5.1 Rituximab Biosimilar – Sandoz
3.5.2 Rituximab Biosimilar – Amgen
3.5.3 Rituximab Biosimilar – Boehringer Ingelheim
3.5.4 Rituximab Biosimilar – Dr. Reddy’s Laboratories
3.5.5 Rituximab Biosimilar – Pfizer
3.5.6 Rituximab Biosimilar – Difficulties Seen in Trials

4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel, 2016
4.1 Sandoz – Company Overview & Analysis
4.1.1 Sandoz Biosimilar Products
4.1.2 Sandoz Biosimilars Market Forecast, 2016-2026
4.1.3 Sandoz Biosimilars R&D Pipeline & Future Outlook
4.1.3.1 GP2017 – Adalimumab Biosimilar
4.1.3.2 GP2015 – Etanercept Biosimilar
4.1.3.3 GP2013 – Rituximab Biosimilar
4.1.3.4 HX575 – Epoetin-alfa Biosimilar
4.1.3.5 EP2006 – Zarzio (Filgrastim Biosimilar)
4.2 Teva Pharmaceuticals – Company Overview & Analysis
4.2.1 Teva Biosimilar Products
4.2.2 Teva Biosimilar Market Forecast, 2016-2026
4.2.3 Teva Biosimilar Pipeline & Future Outlook
4.3 Hospira – Company Overview & Analysis
4.3.1 Hospira Biosimilar Products
4.3.2 Hospira Biosimilars Pipeline & Future Strategies
4.3.2.1 Retacrit
4.3.2.2 Celltrion Partnerships
4.3.2.3 NovaQuest Partnership
4.4 STADA Arzneimittel – Company Overview & Analysis
4.4.1 STADA Biosimilar Products
4.4.2 STADA Biosimilars Pipeline & Future Outlook
4.4.2.1 Biosimilar Pegfilgrastim
4.4.2.2 Biosimilar Rituximab
4.4.2.3 Biosimilar Teriparatide
4.5 Mylan – Company Biosimilar & Analysis
4.5.1 Mylan Biosimilar Products
4.5.2 Mylan Biosimilar Market Forecast, 2016-2026
4.5.3 Mylan Biosimilars Pipeline & Future Outlook
4.5.3.1 Mylan and Momenta – Biosimilars Product Development Programme
4.5.3.2 Biosimilar Insulin Glargine
4.5.3.3 A Series of Biosimilar Monoclonal Antibodies
4.5.3.4 Biosimilar Insulin Lispro & Aspart
4.6 Other Biosimilars Companies in the US
4.6.1 Impax Laboratories Inc. – Company Overview & Analysis
4.6.2 Bristol-Myers Squibb – Company Overview & Analysis
4.6.3 Merck & Co. – Company Overview & Analysis
4.6.4 Eli Lilly – Company Overview & Analysis
4.7 Other Biosimilars Companies in Europe
4.7.1 BioXpress Therapeutics – Company Overview & Analysis
4.7.2 Medice Arzneimittel Pütter GmbH & Co. KG – Company Overview & Analysis
4.7.3 Finox Biotech – Company Overview & Analysis
4.7.4 Actavis – Company Overview & Analysis

5. Leading Biosimilar Manufacturers in China, 2016
5.1 S3Bio – Company Overview & Analysis
5.1.1 3SBio Biosimilar Products
5.1.2 3SBio Biosimilars Market Forecast, 2016-2026
5.1.3 3SBio Biosimilars Pipeline & Future Outlook
5.1.3.1 Second-generation rhEPO products
5.1.3.2 Nadroparin Calcium
5.2 Qilu Pharmaceutical – Company Overview & Analysis
5.2.1 Qilu Pharmaceutical Biosimilar Products
5.2.2 Qilu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.2.2.1 Extensive Pipeline Developments
5.2.2.2 Etanercept Biosimilar
5.2.2.3 Other Biosimilars in Pipeline
5.3 Shanghai Fosun Pharmaceuticals – Company Overview & Analysis
5.3.1 Shanghai Fosun Pharmaceuticals Biosimilar Products
5.3.2 Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategy
5.3.2.1 Trastuzumab Biosimilar
5.3.2.2 Rituximab Biosimilar
5.3.2.3 Acquisitions and Investments
5.4 Tonghua Dongbao – Company Overview & Analysis
5.4.1 Tonghua Dongbao Biosimilar Products
5.4.2 Tonghua Dongbao Biosimilars Pipeline & Future Strategies
5.4.2.1 Biosimilar Insulin Analogues
5.4.2.2 Investments in New Production Plant
5.5 Beijing ShuangLu Pharmaceuticals – Company Overview & Analysis
5.5.1 Beijing ShuangLu Pharmaceuticals Biosimilar Products
5.5.2 Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.6 Other Biosimilars Companies in China
5.6.1 Shanghai CP Guojian – Company Overview & Analysis
5.6.2 Zhejiang Hisun – Company Overview & Analysis
5.6.3 Innovent Biologics – Company Overview & Analysis
5.6.4 Shanghai Celgen Biopharmaceutical – Company Overview & Analysis

6. Leading Biosimilar Manufacturers in India, 2016
6.1 Biocon – Company Overview & Analysis
6.1.1 Biocon Biosimilar Products
6.1.2 Biocon Biosimilars Market Forecast, 2016-2026
6.1.3 Biocon Biosimilars Pipeline & Future Outlook
6.1.3.1 Biosimilar Bevacizumab
6.1.3.2 Biosimilar Adalimumab
6.1.3.3 Biosimilar Pegfilgrastim
6.1.3.4 Biosimilar Trastuzumab
6.1.3.5 Biosimilar Etanercept
6.1.3.6 Biosimilar Recombinant Human Insulin
6.1.3.7 Biosimilar Insulin Glargine
6.1.3.8 Other Biosimilar Insulin
6.2 Dr. Reddy’s Laboratories – Company Overview & Analysis
6.2.1 Dr. Reddy’s Laboratories Biosimilar Products
6.2.2 Dr. Reddy’s Laboratories Biosimilars Pipeline & Future Outlook
6.2.2.1 Merck Serono Collaboration
6.2.2.2 Increasing Focus on Emerging Markets
6.3 Wockhardt – Company Overview & Analysis
6.3.1 Wockhardt Biosimilar Products
6.3.2 Wockhardt Biosimilars Pipeline & Future Outlook
6.4 Zydus Cadila – Company Overview & Analysis
6.4.1 Zydus Cadila Biosimilar Products
6.4.2 Zydus Cadila Biosimilars Pipeline & Future Outlook
6.4.2.1 Biosimilar Interferon beta-1b
6.4.2.2 Oncology Biosimilars
6.4.2.3 Inflammation Biosimilars
6.4.2.4 Thrombolytic Biosimilars
6.4.2.5 Fertility Biosimilars
6.5 Ranbaxy – Company Overview & Analysis
6.5.1 Ranbaxy Biosimilar Products
6.5.2 Ranbaxy Biosimilars Pipeline & Future Outlook
6.6 Reliance Life Sciences – Company Overview & Analysis
6.6.1 Reliance Life Sciences Biosimilar Products
6.6.2 Reliance Life Sciences Biosimilars Pipeline & Future Outlook
6.7 Intas Biopharmaceuticals – Company Overview & Analysis
6.7.1 Intas Biopharmaceuticals Biosimilar Products
6.7.2 Intas Biopharmaceuticals Biosimilars Pipeline & Future Outlook
6.7.2.1 Biosimilar Pegylated Interferon
6.7.2.2 Biosimilar Etanercept
6.7.2.3 Biosimilar Ranibizumab
6.7.2.4 Overseas Opportunities
6.8 Other Indian Biosimilars Companies
6.8.1 Emcure Pharmaceuticals – Company Overview & Analysis
6.8.2 Shreya Life Sciences – Company Overview & Analysis
6.8.3 Cipla – Company Overview & Analysis
6.8.4 Shantha Biotechnics – Company Overview & Analysis

7. Leading Biosimilar Manufacturers in Latin America, 2016
7.1 Probiomed – Company Overview & Analysis
7.1.1 Probiomed Biosimilar Products
7.1.2 Probiomed Biosimilars Pipeline & Future Strategies
7.2 Biosidus – Company Overview & Analysis
7.2.1 Biosidus Biosimilar Products
7.2.2 Biosidus Biosimilars Pipeline & Future Strategies
7.3 Amega Biotech – Company Overview and Analysis
7.3.1 Amega – Biosimilar Products
7.3.2 Amega Biotech Biosimilars Pipeline & Future Strategies
7.4 Other Biosimilars Companies in South America
7.4.1 Bionovis – Company Overview & Analysis
7.4.2 Orygen Biotecnologia – Company Overview & Analysis
7.4.3 Recepta – Company Overview & Analysis

8. Leading Biosimilar Manufacturers in the Rest of the World, 2016
8.1 Celltrion – Company Overview & Analysis
8.1.1 Celltrion Biosimilar Products
8.1.2 Celltrion Biosimilars Pipeline & Future Strategies
8.1.2.1 Trastuzumab Biosimilar
8.1.2.2 Rituximab Biosimilar
8.1.2.3 Four Further Development mAb Biosimilar
8.2 LG Life Sciences – Company Overview & Analysis
8.2.1 LG Life Sciences Biosimilar Products
8.2.2 LG Life Science Biosimilars Pipeline & Future Strategies
8.3 Dong-A – Company Overview & Analysis
8.3.1 Dong-A Biosimilar Products
8.3.2 Dong-A Biosimilars Pipeline & Future Strategies
8.3.2.1 DA-3803 – hCG Biosimilar
8.3.2.2 DA-3031 – Pegylated Filgrastim Biosimilar
8.3.2.3 DA-3880 – Darbepoetin Alpha Biosimilar
8.3.2.4 DA-3111 – Trastuzumab Biosimilar
8.3.2.5 DA-3113 – Adalimumab Biosimilar
8.3.2.6 3853 – Etanercept Biosimilar
8.3.2.7 DA-3808 – Recombinant Factor VIII Biosimilar
8.4 Bioton – Company Overview & Analysis
8.4.1 Bioton’s Biosimilar Products
8.4.2 Bioton’s Biosimilars Pipeline & Future Strategies
8.5 Biocad – Company Overview & Analysis
8.5.1 Biocad’s Biosimilar Products
8.5.2 Biocad’s Biosimilars Pipeline & Future Strategies
8.6 Other Biosimilars Companies in the RoW
8.6.1 Gedeon-Richter – Company Overview & Analysis
8.6.2 Egis Pharmaceuticals – Company Overview & Analysis
8.6.3 JCR Pharmaceuticals – Company Overview & Analysis
8.6.4 Nippon Kayaku – Company Overview & Analysis
8.6.5 Fujifilm Kyowa Kirin Biologics – Company Overview & Analysis
8.6.6 Daiichi Sankyo – Company Overview & Analysis

9. Qualitative Analysis of Biosimilars Market, 2016-2026
9.1 SWOT Analysis of the Global Biosimilars Industry and Market, 2016-2026
9.1.1 Strengths
9.1.1.1 Savings in Healthcare Costs
9.1.1.2 Strong Pipeline – Innovation and Growth of the Biosimilars Market
9.1.1.3 Entry of Biosimilars Into the US market
9.1.2 Weaknesses
9.1.2.1 R&D Cost – Pricing Companies Out of Biosimilars?
9.1.2.2 Developing Market – Biosimilars Still Niche
9.1.2.3 Unclear Regulations for Biosimilars
9.1.3 Opportunities
9.1.3.1 Patent Expiry for Branded Biologics
9.1.3.2 Increase in Prevalence of Chronic Diseases
9.1.3.3 Innovation – New Technology Driving Biosimilar Growth
9.1.3.4 Focus on Biosimilar Monoclonal Antibodies and Insulin
9.1.4 Threats
9.1.4.1 Stricter Regulations for Biosimilar Manufacturers
9.1.4.2 Lawsuits – Patent Protection from Innovator Biologics
9.1.4.3 Biobetters – Removing the Need for Biosimilars?
9.2 STEP Analysis of the Global Biosimilars Industry and Market: 2016 -2026
9.2.1 Social Factors
9.2.1.1 Global Healthcare – An Ambitious Aim?
9.2.1.2 Raising Awareness will Lead to Greater Product Adoption
9.2.2 Technological Factors
9.2.2.1 Innovation Driven – Growing Manufacturing Efficiency
9.2.2.2 High Technological Expertise Needed
9.2.3 Economic Factors
9.2.3.1 R&D for Biosimilar Development – Cost Barriers
9.2.3.2 Healthcare Savings – Cutting Spending and Costs
9.2.4 Political Factors
9.2.4.1 Government Influence – Funding for Biosimilar Industry?
9.2.4.2 International Cooperation Required
9.2.4.3 Regularly Updated Guideline Will Benefit Developers

10. Research Interviews
10.1 Mr Chandru Chawla, Head of Corporate Strategy, Cipla
10.1.1 Cipla Overview
10.1.2 Introducing Cipla’s Biosimilars Landscape
10.1.3 Cipla’s Biosimilars Strategy: Collaboration & Competition
10.1.4 Future Directions for the Biosimilars Industry
10.2 Mr Peter Keller, Chief Business Officer, Selecta Bioscience
10.2.1 Novel Technology Platform
10.2.2 Application with Drugs
10.2.3 Biosimilar Vaccines – Future Potential?
10.2.4 Future Strategies
10.2.5 Biosimilar Market Outlook
10.3 Industry Source from a Leading Indian Biopharmaceutical Company
10.3.1 Indian Pharmaceutical and Biosimilars Market Overview
10.3.2 Indian Patent Protection – Effect on Biosimilar Industry
10.3.3 Partnerships among Biosimilar Companies
10.3.4 Future Developments in the Indian Biosimilars Market

11. Conclusions
11.1 Market Leaders Among Biosimilar Manufacturers
11.2 Will Sandoz Retain its Position as Market Leader?
11.3 Which Companies Are Best Placed to Lead in Future?
11.4 Big Pharma Companies Will Try Gain Market Entry
11.5 Contribution of Chinese and Indian Companies will Grow
11.6 Strong R&D Pipeline – Driver for Growth
11.7 Concluding Remarks

List of Tables
Table 2.1 Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 2.2 Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.1 Humira Biologic Analysis, 2016
Table 3.2 Remicade Biologic Analysis, 2016
Table 3.3 Enbrel Biologic Analysis, 2016
Table 3.4 Aranesp: Biologic Analysis, 2016
Table 3.5 Rituxan: Biologic Analysis, 2016
Table 4.1 Sandoz: Company Overview, 2016
Table 4.2 Sandoz: Biosimilar Product Portfolio, 2016
Table 4.3 Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.4 Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 4.5 Sandoz: Biosimilar Developments Overview, 2016
Table 4.6 Teva: Company Overview, 2016
Table 4.7 Teva: Biosimilar Developments Overview, 2016
Table 4.8 Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.9 Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 4.10 Hospira: Company Overview, 2016
Table 4.11 Hospira: Biosimilars Overview, 2016
Table 4.12 Hospira: Biosimilar Developments Overview, 2016
Table 4.13 Stada Arzneimittel: Company Overview, 2016
Table 4.14 Stada Arzneimittel: Biosimilars Overview, 2016
Table 4.15 Stada Arzneimittel: Biosimilar Developments Overview, 2016
Table 4.16 Mylan: Company Overview, 2016
Table 4.17 Mylan: Biosimilars Overview, 2016
Table 4.18 Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.19 Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 4.20 Mylan: Biosimilar Developments Overview, 2016
Table 4.21 Impax Laboratories: Company Overview, 2016
Table 4.22 Bristol-MyersSquibb: Company Overview, 2016
Table 4.23 Merck & Co.: Company Overview, 2016
Table 4.24 Merck & Co.: Biosimilars Product Pipeline, 2016
Table 4.25 Eli Lilly: Company Overview, 2016
Table 4.26 Eli Lilly: Biosimilars Product Portfolio, 2016
Table 4.27 BioXpress Therapeutics: Company Overview, 2016
Table 4.28 Medice Arzneimittel Pütter: Company Overview, 2016
Table 4.29 Finox Biotech: Company Overview, 2016
Table 4.30 Actavis: Company Overview, 2016
Table 5.1 3SBio: Company Overview, 2016
Table 5.2 3SBio: Biosimilars Overview, 2016
Table 5.3 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 5.4 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 5.5 3SBio: Biosimilar Developments Overview, 2016
Table 5.6 Qilu Pharmaceutical: Company Overview, 2016
Table 5.7 Qilu Pharmaceutical: Biosimilars Overview, 2016
Table 5.8 Qilu Pharmaceutical: Biosimilar Developments Overview, 2016
Table 5.9 Shanghai Fosun: Company Overview, 2016
Table 5.10 Shanghai Fosun: Biosimilars Overview, 2016
Table 5.11 Shanghai Fosun: Biosimilar Developments Overview, 2016
Table 5.12 Tonghua Dongbao: Company Overview, 2016
Table 5.13 Tonghua Dongbao: Biosimilars Overview, 2016
Table 5.14 Tonghua Dongbao: Biosimilar Developments Overview, 2016
Table 5.15 Beijing ShuangLu: Company Overview, 2016
Table 5.16 Beijing ShuangLu: Biosimilars Overview, 2016
Table 5.17 Beijing ShuangLu: Biosimilar Developments Overview, 2016
Table 5.18 Shanghai CP Guojian: Company Overview, 2016
Table 5.19 Zhejiang Hisun: Company Overview, 2016
Table 5.20 Innovent Biologics: Company Overview, 2016
Table 5.21 Shanghai Celgen Biopharmaceutical: Company Overview, 2016
Table 6.1 Biocon: Company Overview, 2016
Table 6.2 Biocon: Biosimilars Product Portfolio, 2016
Table 6.3 Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 6.4 Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 6.5 Biocon: Biosimilars Pipeline, 2016
Table 6.6 Dr. Reddy’s Laboratories: Company Overview, 2016
Table 6.7 Dr. Reddy’s Laboratories: Biosimilar Products, 2016
Table 6.8 Dr. Reddy’s Laboratories: Biosimilars Pipeline, 2016
Table 6.9 Wockhardt: Company Overview, 2016
Table 6.10 Wockhardt: Biosimilar Products, 2016
Table 6.11 Wockhardt: Biosimilars Pipeline, 2016
Table 6.12 Zydus Cadila: Company Overview, 2016
Table 6.13 Zydus Cadila: Biosimilars Product Portfolio, 2016
Table 6.14 Zydus Cadila: Biosimilars Pipeline, 2016
Table 6.15 Ranbaxy: Company Overview, 2016
Table 6.16 Ranbaxy: Biosimilars Product Portfolio, 2016
Table 6.17 Zenotech: Biosimilars Pipeline, 2016
Table 6.18 Reliance Life Sciences: Company Overview, 2016
Table 6.19 Reliance Life Sciences: Biosimilar Products, 2016
Table 6.20 Reliance Life Sciences: Biosimilars Pipeline, 2016
Table 6.21 Intas Biopharmaceuticals: Company Overview, 2016
Table 6.22 Intas Biopharmaceuticals: Biosimilar Products Portfolio, 2016
Table 6.23 Intas Biopharmaceuticals: Biosimilars Pipeline, 2016
Table 6.24 Emcure Pharmaceuticals: Company Overview, 2016
Table 6.25 Shreya Life Sciences: Company Overview, 2016
Table 6.26 Cipla: Company Overview, 2016
Table 6.27 Shantha Biotechnics: Company Overview, 2016
Table 7.1 Probiomed: Company Overview, 2016
Table 7.2 Probiomed Biosimilars Product Portfolio, 2016
Table 7.3 Biosidus: Company Overview, 2016
Table 7.4 Biosidus: Biosimilars Product Portfolio, 2016
Table 7.5 Biosidus: Biosimilars Pipeline, 2016
Table 7.6 Amega Biotech: Company Overview, 2016
Table 7.7 Amega Biotech: Biosimilars Product Portfolio , 2016
Table 7.8 Bionovis: Company Overview, 2016
Table 7.9 Orygen Biotechnologia: Company Overview, 2016
Table 7.10 Recepta: Company Overview, 2016
Table 8.1 Celltrion: Company Overview, 2016
Table 8.2 Celltrion: Biosimilars, 2016
Table 8.3 Celltrion: Biosimilars Product Pipeline, 2016
Table 8.4 LG Life Sciences: Company Overview, 2016
Table 8.5 LG Life Sciences: Biosimilars Product Portfolio, 2016
Table 8.6 LG Life Sciences: Biosimilars Pipeline, 2016
Table 8.7 Dong-A: Company Overview, 2016
Table 8.8 Dong-A: Biosimilar Product Portfolio, 2016
Table 8.9 Dong-A: Biosimilar Pipeline, 2016
Table 8.10 Bioton: Company Overview, 2016
Table 8.11 Bioton: Biosimilars Product Portfolio, 2016
Table 8.12 Biocad: Company Overview, 2016
Table 8.13 Biocad: Biosimilars Product Portfolio, 2016
Table 8.14 Biocad: Biosimilars Pipeline, 2016
Table 8.15 Gedeon-Richter: Company Overview, 2016
Table 8.16 Egis Pharmaceuticals: Company Overview, 2016
Table 8.17 JCR Pharmaceuticals: Company Overview, 2016
Table 8.18 Nippon Kayaku: Company Overview, 2016
Table 8.19 Fujifilm Kyowa Kirin Biologics: Company Overview, 2016
Table 8.20 Daiichi Sankyo: Company Overview, 2016

List of Figures
Figure 1.1 Biosimilars Market Segmentation, 2016
Figure 2.1 Global Biosimilar Market: Revenue Forecast ($bn), 2015-2026
Figure 2.2 Global Biosimilar Market Drivers, 2016
Figure 2.3 Global Biosimilar Market Restraints, 2016
Figure 4.1 Sandoz: Biosimilar Products Revenue Forecast ($bn), 2015-2026
Figure 4.2 Teva Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2015-2026
Figure 4.3 Mylan Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2015-2026
Figure 5.1 S3Bio Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2015-2026
Figure 6.1 Biocon: Biosimilar Products Revenue Forecast ($bn), 2015-2026
Figure 9.1 SWOT Analysis of the Biosimilars Market, 2016
Figure 9.2 STEP Analysis of the Biosimilars Market, 2016

【レポートのキーワード】

バイオシミラー(バイオ後続品)、メーカー、企業分析

★調査レポート[世界のトップ25バイオシミラー(バイオ後続品)メーカー分析2016-2026] ( Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026 / VGAIN6041543) 販売に関する免責事項
[世界のトップ25バイオシミラー(バイオ後続品)メーカー分析2016-2026] ( Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026 / VGAIN6041543) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆